Title: Opioid Treatment Surge Act
Policy area: Health

Summary:
Opioid Treatment Surge ActThis bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3105 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 3105

     To establish an annual fee applicable to opioid manufacturers.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              June 5, 2019

 Ms. Bonamici introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
     To establish an annual fee applicable to opioid manufacturers.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Opioid Treatment Surge Act''.

SEC. 2. ANNUAL FEE.

    (a) In General.--For each of the 10 calendar years immediately 
proceeding the date of enactment of this Act, the Secretary of Health 
and Human Services shall assess a fee against each prescription drug 
manufacturer that, at any time during the period beginning on January 
1, 1999, and ending on the calendar year immediately preceding the year 
in which the fee is assessed, manufactured any opioid drug (other than 
a drug described in subsection (b)). Such fee, with respect to such a 
manufacturer, shall be in an amount, as determined by such Secretary, 
that bears the same relationship to $2,000,000,000 as the market share 
of any such opioid drugs manufactured by such manufacturer during the 
period for which the fee is being assessed bears to the total market 
for opioid drugs (excluding such drugs described in subsection (b)) 
during such period.
    (b) Exceptions.--The fee described in subsection (a) shall not 
apply with respect to any opioid drug used exclusively for the 
treatment of--
            (1) opioid addiction, as part of a medically assisted 
        treatment effort; or
            (2) cancer or hospice patients.
    (c) Transfers To Block Grant Programs.--For each year that the 
Secretary of Health and Human Services assesses fees under subsection 
(a), the Secretary of the Treasury shall transfer from the general fund 
of the Treasury to the Secretary of Health and Human Services an amount 
equal to the amount of such fees, for purposes of carrying out the 
substance abuse prevention and treatment block grant under subpart II 
of part B of title XIX of the Public Health Service Act (42 U.S.C. 
300x-21 et seq.).
                                 <all>